# A Study of Itacitinib in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Participants With Myelofibrosis

> **NCT03144687** · PHASE2 · COMPLETED · sponsor: **Incyte Corporation** · enrollment: 23 (actual)

## Conditions studied

- MPN (Myeloproliferative Neoplasms)

## Interventions

- **DRUG:** Itacitinib
- **DRUG:** Ruxolitinib

## Key facts

- **NCT ID:** NCT03144687
- **Lead sponsor:** Incyte Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-01-26
- **Primary completion:** 2020-03-14
- **Final completion:** 2021-06-01
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2022-06-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03144687

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03144687, "A Study of Itacitinib in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Participants With Myelofibrosis". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03144687. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*